What are the  Most  Common Barriers to Cannabis Research?

  • Legal, government sanctioned  access to the cannabis plant.

  • Lack of familiarity with area of study

  • Uneducated hospital ethics committees

  • Cannabis is still classified as schedule 1 drug

  • Stigma (professional peer as well as hospital board of directors not wanting to take a risk or be associated with "new" cannabis

  • Limited experience from all parts (access to materials, Ethics committees (EC's), national regulators)

  • No turn-key solution that has experience at all stages

How does EndoCRO address those barriers?

Israeli regulators and hospital ethics committees have a rich history and a strong desire to perform studies on cannabis medicine. With over 50 years of experience, we have simply been doing it longer and more deeply than any other country.  Israel boasts a robust medical cannabis program and in fact is home to the most licensed medical users per capita worldwide (upwards of 22,000 patients). Israel not only has the technical know-how but also has the infrastructure to provide medical grade cannabis products. Israel is approved by the FDA to perform OUS (outside of US) studies and has been a site for all major pharma companies at all stages.  EndoCRO has a vast  professional network of connections,  and the  professionalism and expertise that enables our study partners to perform the highest level clinical studies in Medical Cannabis in the world.

 

 

 

 

 

© 2016 by iCAN israel-cannabis.com endoCRO

CONTACT US

SUBS C/O endoCRO

5 Ha'uman St 

North Industrial Zone
Beit Shemesh 99000

Israel

e.  info@endocro.com

t.  +972-52-591-2679